HONG KONG, March 2021 /PRNewswire/ — A Hong Kong Baptist University-led (HKBU) research team has developed a novel drug which has the potential to become a next-generation treatment for cancers associated with Epstein–Barr virus (EBV). The peptide-linked drug, which is responsive to the acidic environment found in tumours, is the first known agent to have successfully targeted two viral proteins that […]

Continue Reading